Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events
https://doi.org/10.18087/cardio.2020.12.n1158
Abstract
Asymptomatic hyperuricemia (HU) is widespread in the population. Results of multiple studies have demonstrated independent associations between increased levels of uric acid and risk of arterial hypertension, cardiovascular diseases, and chronic kidney disease. HU is considered as an independent predictor of cardiovascular and all-cause mortality. Despite the extensive study of this issue, there is still no unified answer to questions regarding the necessity of urate-lowering therapy in asymptomatic HU, whereas results of studies on the effect of this therapy on outcomes of cardiovascular and kidney diseases are controversial. This review summarized the basic, currently available information on this issue.
Keywords
Asymptomatic hyperuricemia,
cardiovascular risk,
chronic kidney disease,
urate-lowering therapy,
xanthine oxidase inhibitors
Supporting agencies: No conflict of interest is reported.
About the Authors
Zh. D. Kobalava
People`s Friendship University of Russia (RUDN University), Moscow
Russian Federation
chef of the department of the internal diseases with the course in cardiology and functional diagnostics named after V.S. Moiseev
Russian Federation
chef of the department of the internal diseases with the course in cardiology and functional diagnostics named after V.S. Moiseev
E. A. Troitskaya
People`s Friendship University of Russia (RUDN University), Moscow
Russian Federation
associate professor, department of internal diseases with the course in cardiology and functional diagnostics named after V.S.Moiseev
Russian Federation
associate professor, department of internal diseases with the course in cardiology and functional diagnostics named after V.S.Moiseev
References
1. Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Seminars in Arthritis and Rheumatism. 2017;46(4):457–64. DOI: 10.1016/j.semarthrit.2016.07.015
2. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease: Journal of Hypertension. 2015;33(9):1729–41. DOI: 10.1097/HJH.0000000000000701
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953– 2041. DOI: 10.1097/HJH.0000000000001940
4. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786
5. Perez-Ruiz F, Marimon E, Chinchilla SP. Hyperuricaemia with deposition: latest evidence and therapeutic approach. Therapeutic Advances in Musculoskeletal Disease. 2015;7(6):225–33. DOI: 10.1177/1759720X15599734
6. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM et al. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. 2018;169(8):535– 42. DOI: 10.7326/M18-1167
7. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–31. DOI: 10.1056/NEJMoa1707914
8. Feig DI, Soletsky B, Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008;300(8):924–32. DOI: 10.1001/jama.300.8.924
9. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and Experimental Nephrology. 2015;19(6):1044–53. DOI: 10.1007/s10157-015-1095-1
10. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertension Research. 2014;37(10):919–25. DOI: 10.1038/hr.2014.107
11. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clinical Journal of the American Society of Nephrology. 2010;5(8):1388–93. DOI: 10.2215/CJN.01580210
12. Segal MS, Srinivas TR, Mohandas R, Shuster JJ, Wen X, Whidden E et al. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. Journal of the American Society of Hypertension. 2015;9(8):610-619.e1. DOI: 10.1016/j.jash.2015.05.009
13. Assadi F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. Journal of Nephrology. 2014;27(1):51–6. DOI: 10.1007/s40620-013-0009-0
14. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A et al. Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial. American Journal of Kidney Diseases. 2015;65(4):543–9. DOI: 10.1053/j.ajkd.2014.11.016
15. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of highdose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. The Lancet. 2010;375(9732):2161–7. DOI: 10.1016/S0140-6736(10)60391-1
16. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–71. DOI: 10.1161/CIRCULATIONAHA.114.014536
17. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al. Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial. Kidney and Blood Pressure Research. 2012;35(3):153–60. DOI: 10.1159/000331453
18. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clinical Endocrinology. 2015;83(4):475–82. DOI: 10.1111/cen.12673
19. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al. A Randomized Study of Allopurinol on Endothelial Function and Estimated Glomular Filtration Rate in Asymptomatic Hyperuricemic Subjects with Normal Renal Function. Clinical Journal of the American Society of Nephrology. 2011;6(8):1887–94. DOI: 10.2215/ CJN.11451210
20. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Kidney Diseases. 2015;66(6):945–50. DOI: 10.1053/j.ajkd.2015.05.017
21. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases. 2018;72(6):798–810. DOI: 10.1053/j.ajkd.2018.06.028
22. Agarwal V, Hans N, Messerli FH. Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis. The Journal of Clinical Hypertension. 2013;15(6):435–42. DOI: 10.1111/j.1751-7176.2012.00701.x
23. Qu L, Jiang H, Chen J. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of Medicine. 2017;49(2):142–56. DOI: 10.1080/07853890.2016.1243803
24. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine. 2010;170(15):1358–64. DOI: 10.1001/archinternmed.2010.198
25. Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS et al. Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Journal of the American College of Cardiology. 2008;51(24):2301–9. DOI: 10.1016/j.jacc.2008.01.068
26. Sinyutina E.A., Alexandria L.G., Trayanova T.G., Moiseev V.S. Hyperuricemia in patients with chronic heart failure. Cardiorenal effects of allopurinol. Clinical nephrology. 2012;4:46–50.
27. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Failure. 2017;4(1):40–5. DOI: 10.1002/ehf2.12112
28. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG et al. High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease. Journal of the American College of Cardiology. 2013;61(9):926–32. DOI: 10.1016/j.jacc.2012.09.066
29. de Abajo FJ, Gil MJ, Rodríguez A, García-Poza P, Álvarez A, Bryant V et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101(9):679–85. DOI: 10.1136/heartjnl-2014-306670
30. Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. The American Journal of Medicine. 2016;129(3):299-306. e2. DOI: 10.1016/j.amjmed.2015.11.003
31. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine. 2018;378(13):1200– 10. DOI: 10.1056/NEJMoa1710895
32. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis & Rheumatology. 2018;70(11):1702–9. DOI: 10.1002/art.40583
33. Bubb MR. Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment–Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al. Arthritis & Rheumatology. 2019;71(8):1391–2. DOI: 10.1002/art.40914
34. Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L. Febuxostat and Cardiovascular Events: A Systematic Review and MetaAnalysis. International Journal of Rheumatology. 2019;2019:1076189. DOI: 10.1155/2019/1076189
35. Jansen TLThA, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clinical Rheumatology. 2019;38(1):263–5. DOI: 10.1007/s10067-018-4396-4
36. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. European Heart Journal. 2019;40(22):1778–86. DOI: 10.1093/eurheartj/ehz119
37. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology. 2015;16(1):58. DOI: 10.1186/s12882-015-0047-z
38. Wang H, Wei Y, Kong X, Xu D. Effects of Urate-Lowering Therapy in Hyperuricemia on Slowing the Progression of Renal Function: A Meta-Analysis. Journal of Renal Nutrition. 2013;23(5):389–96. DOI: 10.1053/j.jrn.2012.08.005
39. Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Renal Failure. 2018;40(1):289–97. DOI: 10.1080/0886022X.2018.1456463
40. Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLOS ONE. 2017;12(11):e0187550. DOI: 10.1371/journal.pone.0187550
41. Eliseev MS. Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy. Modern Rheumatology Journal. 2018;12(1):60–5. DOI: 10.14412/1996-7012-2018-1-60-65
42. Borghi C, Tykarski A, Widecka K, Filipiak KJ, DomienikKarłowicz J, Kostka-Jeziorny K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology Journal. 2018;25(5):545–63. DOI: 10.5603/CJ.2018.0116
43. Chazova I.E., Zhernakova Yu.V., Kisliak O.A., Nedogoda S.V., Podzolkov V.I., Oshchepkova E.V. et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019;16(4):8–21. DOI: 10.26442/2075082X.2019.4.190686
44. Carnovale C, Venegoni M, Clementi E. Allopurinol Overuse in Asymptomatic Hyperuricemia: A Teachable Moment. JAMA Internal Medicine. 2014;174(7):1031–2. DOI: 10.1001/jamainternmed.2014.1427
Review
For citations:
Kobalava Zh.D., Troitskaya E.A. Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events. Kardiologiia. 2020;60(12):104-109. (In Russ.) https://doi.org/10.18087/cardio.2020.12.n1158
Views:
12684
Email this article 
Post a Comment 
